IRWDIronwood Pharmaceuticals, Inc.

IRWD Stock Price, Valuation & Chart | Ironwood Pharmaceuticals, Inc.

$4.410+0.14 (+3.28%)

At close · 02 Sept 2026, 08:00 pm

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic IRWD intrinsic value IRWD calculated fair value vs price

Overview Financials Dividends Ratios

IRWD Historical price chart

IRWD Key Stats

Fair Value

Disclaimer

Disclaimer: This fair value estimate is for informational purposes only and should not be considered as investment advice. Fair value calculations are based on DCF (Discounted Cash Flow), P/E Multiple, and P/S Multiple models and assumptions that may not reflect actual market conditions. Always conduct your own research and consult with a financial advisor before making investment decisions.

Unlock

Market Capitalization725.94M

PE Ratio5.65

EPS0.78

Trading Volume2.43M

Today's High/Low4.47/4.26

Dividend Yield0.00

52 Week High/Low5.78/1.01

Shares Outstanding164.61M

IRWD Financial Statement

IRWD Analyst ratings

IRWD Analysis & performance metrics

IRWD Company profile

Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate…

Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and Mexico,…

IRWD Management team

Name

Position

Mike Nanfito

Vice President of Sales & Sales Excellence

Greg MartiniCFO

Senior Vice President, Chief Financial Officer & Investor Relations

John Minardo

Senior Vice President, Chief Legal Officer & Secretary

Tammi Gaskins

Senior Vice President & Chief Commercial Officer.

Ronald Silver

Senior Vice President, Corporate Controller & Principal Accounting Officer

Thomas A. McCourtCEO

Chief Executive Officer & Director

Michael Shetzline M.D., Ph.D.

Chief Medical Officer, Senior Vice President and Head of Research & Drug Development

Rosario Lobrutto M.B.A., M.S., Ph.D.

Vice President & Global Head of Technical Operations

Name

Position

Mike Nanfito

Vice President of Sales & Sales Excellence

Greg MartiniCFO

Senior Vice President, Chief Financial Officer & Investor Relations

John Minardo

Senior Vice President, Chief Legal Officer & Secretary

Tammi Gaskins

Senior Vice President & Chief Commercial Officer.

Ronald Silver

Senior Vice President, Corporate Controller & Principal Accounting Officer

Thomas A. McCourtCEO

Chief Executive Officer & Director

Michael Shetzline M.D., Ph.D.

Chief Medical Officer, Senior Vice President and Head of Research & Drug Development

Rosario Lobrutto M.B.A., M.S., Ph.D.

Vice President & Global Head of Technical Operations

Management Team

Mike Nanfito

Vice President of Sales & Sales Excellence

Greg MartiniCFO

Senior Vice President, Chief Financial Officer & Investor Relations

John Minardo

Senior Vice President, Chief Legal Officer & Secretary

Tammi Gaskins

Senior Vice President & Chief Commercial Officer.

Ronald Silver

Senior Vice President, Corporate Controller & Principal Accounting Officer

Thomas A. McCourtCEO

Chief Executive Officer & Director

Michael Shetzline M.D., Ph.D.

Chief Medical Officer, Senior Vice President and Head of Research & Drug Development

Rosario Lobrutto M.B.A., M.S., Ph.D.

Vice President & Global Head of Technical Operations

Management

Mike Nanfito

Vice President of Sales & Sales Excellence

Greg MartiniCFO

Senior Vice President, Chief Financial Officer & Investor Relations

John Minardo

Senior Vice President, Chief Legal Officer & Secretary

Tammi Gaskins

Senior Vice President & Chief Commercial Officer.

Ronald Silver

Senior Vice President, Corporate Controller & Principal Accounting Officer

Thomas A. McCourtCEO

Chief Executive Officer & Director

Michael Shetzline M.D., Ph.D.

Chief Medical Officer, Senior Vice President and Head of Research & Drug Development

Rosario Lobrutto M.B.A., M.S., Ph.D.

Vice President & Global Head of Technical Operations

Total 8 executives

IRWD Frequently asked questions

What is Ironwood Pharmaceuticals, Inc. (IRWD) Stock Price?

Current stock price of Ironwood Pharmaceuticals, Inc. (IRWD) stock is $4.410. The stock price is +3.28% higher in the session. The intraday range can be seen from this page. Volume of Ironwood Pharmaceuticals, Inc. (IRWD) stock is 2.43M.

Last updated at 02 Sept 2026, 08:00 pm.

Why is the Ironwood Pharmaceuticals, Inc. (IRWD) stock price going up or down today?

The stock price of Ironwood Pharmaceuticals, Inc. (IRWD) can change with earnings, company news, and overall market sentiment. Ironwood Pharmaceuticals, Inc. operates in the Healthcare / Drug Manufacturers - Specialty & Generic market, so sector-wide moves can also affect the share price. Use the live price, percentage change, and volume on this page to judge whether a move looks meaningful.

Is the Ironwood Pharmaceuticals, Inc. stock expensive at its current price?

Whether Ironwood Pharmaceuticals, Inc. looks expensive depends on valuation metrics versus its growth outlook. The P/E ratio shown for IRWD on this page is 5.65. EPS on this page is 0.78. Compare those figures with peers and growth expectations before deciding if the current Ironwood Pharmaceuticals, Inc. price is justified.

How has the stock price of Ironwood Pharmaceuticals, Inc. (IRWD) performed historically?

Historical performance for Ironwood Pharmaceuticals, Inc. (IRWD) is shown on the price chart on this page. Review multi-period moves alongside volume to see how IRWD reacted to past earnings and market events.

Should I buy Ironwood Pharmaceuticals, Inc. (IRWD) stock, at this price?

Buying Ironwood Pharmaceuticals, Inc. (IRWD) depends on your risk tolerance, time horizon, and portfolio needs. As a Healthcare name, weigh the live quote, key stats, and valuation links on this page rather than a single price point.